Tanshinone IIA-loaded reconstituted high density lipoproteins: Atherosclerotic plaque targeting mechanism in a foam cell model and pharmacokinetics in rabbits

Pharmazie

Volumn 67, Issue 4, 2012, Pages 324-330

  Zhang, Wenli ^a   Li, Jin ^a   Liu, Jianping ^a   Wu, Zimei ^b   Xu, Yiming ^c   Wang, Ji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR BI; TANSHINONE IIA; ABIETANE DERIVATIVE; CARDIOVASCULAR AGENT; DRUG CARRIER; LIPOSOME; NANOPARTICLE; TANSHINONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CIRCULAR DICHROISM; CIRCULATION TIME; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG TARGETING; FOAM CELL; IN VIVO STUDY; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PHAGOCYTOSIS; PROTEIN LIPID INTERACTION; PROTEIN SECONDARY STRUCTURE; RABBIT; SINGLE DRUG DOSE; SPECTROSCOPY; SUSPENSION; ZETA POTENTIAL; ANIMAL; BIOLOGICAL MODEL; CELL LINE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ELECTROCHEMISTRY; GENETIC TRANSFECTION; GENETICS; IN VITRO STUDY; INFUSION; PARTICLE SIZE; PLASMID; REPRODUCIBILITY;

ANIMALS; APOLIPOPROTEINS; CARDIOVASCULAR AGENTS; CELL LINE; CIRCULAR DICHROISM; DITERPENES, ABIETANE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ELECTROCHEMISTRY; FOAM CELLS; INFUSIONS, PARENTERAL; LIPOPROTEINS, HDL; LIPOSOMES; MALE; MICE; MODELS, BIOLOGICAL; NANOPARTICLES; PARTICLE SIZE; PHAGOCYTOSIS; PLAQUE, ATHEROSCLEROTIC; PLASMIDS; RABBITS; REPRODUCIBILITY OF RESULTS; TRANSFECTION;

EID: 84861731413     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1055     Document Type: Article

References (56)

1. Ajees A, Anantharamaiah G, Mishra V, Hussain M, Murthy H (2006) Crystal structure of human apolipoprotein AI: insights into its protective effect against cardiovascular diseases. Proc Nat Acad Sci USA 103: 2126-2131.
2. Angelin B, Parini P, Eriksson M (2002) Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL. Atheroscler Suppl 3: 23-30.
3. Assmann G, Nofer J (2003) Atheroprotective effects of high-density lipoproteins. Medicine 54: 321-341.
4. Barter P, Nicholls S, Rye K, Anantharamaiah G, Navab M, Fogelman A (2004) Antiinflammatory properties of HDL. Circ Res 95: 764-772.
5. Bobryshev Y (2006) Monocyte recruitment and foam cell formation in atherosclerosis. Micron 37: 208-222.
6. Bunjes H, Koch MHJ, Westesen K (2003) Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci 92: 1509-1520.
7. Chu MQ, Gu HC, Liu GJ (2002) Study on the preparation of tanshinone proliposomes by spray drying method. Zhongguo Yao Xue Za Zhi 37: 32-35.
8. Collet X, Tall A, Serajuddin H, Guendouzi K, Royer L, Oliveira H, Barbaras R, Jiang X, Francone O (1999) Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor BI. J Lipid Res 40: 1185-1193.
9. Feng M, Cai Q, Huang H, Zhou P (2008) Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm 68: 688-693.
10. Feng M, Pan S, Zhang J, Wang Q, Wu W, Li R (2005) In vitro phagocytic uptake of PEG-PBLG nanoparticles containing amphotericin B. J China Pharm Univ 36: 321-325.
11. Fitzgerald M, Mujawar Z, Tamehiro N (2010) ABC transporters, atherosclerosis and inflammation. Atherosclerosis 211: 361-370.
12. Francone O, Gurakar A, Fielding C (1989) Distribution and functions of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins AI and D that catalyzes the esterification and transfer of cell-derived cholesterol. J Biol Chem 264: 7066-7022.
13. Frank P, Marcel Y (2000) Apolipoprotein AI: structure-function relationships. J Lipid Res 41: 853-872.
14. Han F, Li S,Yin R, Liu H, Xu L (2008) Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: Nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp 315: 210-216.
15. Hao H, Wang G, Cui N, Li J, Xie L, Ding Z (2007) Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr Drug Metab 8: 137-149.
16. Herbert PN, Bernier DN, Cullinane EM, Edelstein L, Kantor MA, Thompson PD (1984) High-density lipoprotein metabolism in runners and sedentary men. JAMA 252: 1034-1037.
17. Hiltunen T, Luoma J, Nikkari T, Yla-Herttuala S (1998) Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation 97: 1079-1086.
18. Jonas A, Wald J, Toohill K, Krul E, Kezdy K (1990) Apolipoprotein AI structure and lipid properties in homogeneous, reconstituted spherical and discoidal high density lipoproteins. J Biol Chem 265: 22123-22129.
19. Joshi M, Pathak S, Sharma S, Patravale V (2008) Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int J Pharm 364: 119-126.
20. Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58: 342-374.
21. Lacko A, Nair M, Paranjape S, Johnson S, McConathy W (2002) High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res 22: 2045-2049.
22. Lehrer S (1971) Solute perturbation of protein fluorescence. Quenching of the tryptophyl fluorescence of model compounds and of lysozyme by iodide ion. Biochemistry 10: 3254-3263.
23. Li H, Zhang Z, Ma L, Chen X (2007) Preparation of tanshinone microemulsion and its absorption in rat intestine in situ. Zhongguo Zhong Yao Za Zhi 32: 1024-1027.
24. Li P,Wang GJ, Li J, Hao HP, Zheng CN (2006) Characterization of metabolites of tanshinone IIA in rats by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 41: 670-684.
25. Li Q, Wang Y, Feng N, Fan Z, Sun J, Nan Y (2008) Novel polymeric nanoparticles containing tanshinone IIA for the treatment of hepatoma. J Drug Target 16: 725-732.
26. Liang L, Chen Y, Xiong S, Zeng Z, Sun M, Zhang H (2007) The inhibitive effect produced by local perfusion of tanshinone IIA nanoparticle on neointimal hyperplasia of rabbit carotid artery following intimal denudation. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 24: 812-816.
27. Liang Z, Mao S, Yin Z, Jin H, Li H, Chu T (2008) Preparation and quality evaluation of intravenous tanshinone II (A) emulsion. Zhongguo Zhong Yao Za Zhi 33: 1249-1252.
28. Libby P, Bonow R, Mann D, Zipes D (2008) Braunwald's heart disease: A textbook of cardiovascular medicine, 8th ed., Saunders Elsevier: Philadelphia, PA.
29. Linsel-Nitschke P, Tall A (2005) HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4: 193-205.
30. Liu J, Zhu J, Du Z, Qin B (2005) Preparation and pharmacokinetic evaluation of Tashinone IIA solid lipid nanoparticles. Drug Dev Ind Pharm 31: 551-556.
31. Lou B, Liao X, Wu M, Cheng P, Yin C, Fei Z (2005) High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol 11: 954-959.
32. Mahley R, Innerarity T (1983) Lipoprotein receptors and cholesterol homeostasis. Biochim Biophys Acta 737: 197-222.
33. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP (2002) Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302: 369-373.
34. Massey J, Gotto A (1979) Contribution of alpha helix formation in human plasma apolipoproteins to their enthalpy of association with phospholipids. J Bioll Chem 254: 9559-9561.
35. McConathy W, Nair M, Paranjape S, Mooberry L, Lacko A (2008) Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 19: 183-188.
36. McGuire KA, Davidson WS, Jonas A (1996) High yield overexpression and characterization of human recombinant proapolipoprotein AI. J Lipid Res 37: 1519-1528.
37. Ogino C, Shibata N, Sasai R, Takaki K, Miyachi Y, Kuroda S, Ninomiya K, Shimizu N (2010) Construction of protein-modified TiO2 nanoparticles for use with ultrasound irradiation in a novel cell-injuring method. Bioorg Med Chem Lett 20: 5320-5325.
38. Phillips J, Wriggers W, Li Z, Jonas A, Schulten K (1997) Predicting the structure of apolipoprotein AI in reconstituted high-density lipoprotein disks. Biophys J 73: 2337-2346.
39. Rensen P, Vrueh, R, Kuiper J, Bijsterbosch M, Biessen E, Berkel T (2001) Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 47: 251-276.
40. Pownall H, Gotto A (1992) Human plasma apolipoproteins in biology and medicine. Structure and Function of Apolipoproteins 1-32.
41. Saito H, Dhanasekaran P, Nguyen D, Deridder E, Holvoet P, Lund-Katz S, Phillips M (2004) α-Helix formation is required for high affinity binding of human apolipoprotein AI to lipids. J Biol Chem 279: 20974-20981.
42. Schöler N, Hahn H, Müller R, Liesenfeld O (2002) Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 231: 167-176.
43. Scherphof G, Roerdink F, Waite M, Parks J (1978) Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim Biophys Acta 542: 296-307.
44. Skajaa T, Cormode D, Jarzyna P, Delshad A, Blachford C, Barazza A, Fisher E, Gordon R, Fayad Z, Mulder W (2010) The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials 32: 206-213.
45. Song X, Fischer P, Chen X, Burton C, Wang J (2009) An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI. Int J Biol Sci 5: 637-646.
46. Su ZR, Liu ZQ, Zhou H (1997) Change of chemical composition of tashinone in concentration and drying technology (1) degradation mechanism of Tashinone IIA under the heat and moisture. Chin Trad Patent Med 19: 5-6.
47. Thomas M, Bhat S, Sorci-Thomas M (2008) Three-dimensional models of HDL apoA-I: implications for its assembly and function. J Lipid Res 49: 1875-1883.
48. Vaisar T, Pennathur S, Green P, Gharib S, Hoofnagle A, Cheung M, Byun J, Vuletic S, Kassim S, Singh P (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Investig 117: 746-756.
49. Xie S, Lee Y, Kim E, Chen L, Ni J, Fang L, Liu S, Lin S, Abe J, Berk B (2009) TR4 nuclear receptor functions as a fatty acid sensor to modulate CD36 expression and foam cell formation. Proc Nat Acad Sci 106: 13353-13358.
50. Yang JT, Wu CSC, Martinez HM. In: Colowick S, Kaplan N, Hirs C, Timasheff S (1986) Methods in enzymology: Enzyme structure: Part K: Academic Press; 130: 208-269.
51. Zannis V, Chroni A, Krieger M (2006) Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 84: 276-294.
52. Zhang Y, Zhou JP, Huo MR (2007) A data analysis program in pharmacokinetics base on Microsoft Excel-Development and validation of PKSlover 1.0. J Math Med 20: 58-61.
53. Zhang W, Gu X, Bai H, Yang R, Dong C, Liu J (2010a) Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. Int J Pharma 391: 313-321.
54. Zhang W, Liu J, Liu X, Chen Z (2009) Stealth tanshinone IIA-loaded solid lipid nanoparticles: effects of poloxamer 188 coating on in vitro phagocytosis and in vivo pharmacokinetics in rats. Yao Xue Xue Bao 44: 1421-1428.
55. Zhang Y, Huo M, Zhou J, Xie S (2010b) PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99: 306-314.
56. Zhao BL, Jiang W, Zhao Y, Hou JW, Xin WJ (1996) Scavenging effects of salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem Mol Biol Int 38: 1171-1182.